Imaging Procedure and Clinical Studies of [F]FP-CIT PET

Overview

Journal Nucl Med Mol Imaging

Publisher Springer

Date 2024 Jun 27

PMID 38932763

Authors

Changhwan Sung

Seung Jun Oh

Jae Seung Kim

Affiliations

Soon will be listed here.

Abstract

N-3-[F]fluoropropyl-2β-carbomethoxy-3β-4-iodophenyl nortropane ([F]FP-CIT) is a radiopharmaceutical for dopamine transporter (DAT) imaging using positron emission tomography (PET) to detect dopaminergic neuronal degeneration in patients with parkinsonian syndrome. [F]FP-CIT was granted approval by the Ministry of Food and Drug Safety in 2008 as the inaugural radiopharmaceutical for PET imaging, and it has found extensive utilization across numerous institutions in Korea. This review article presents an imaging procedure for [F]FP-CIT PET to aid nuclear medicine physicians in clinical practice and systematically reviews the clinical studies associated with [F]FP-CIT PET.

References

Borghammer P . The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. J Parkinsons Dis. 2021; 11(2):455-474. PMC: 8150555. DOI: 10.3233/JPD-202481. View

Park H, Kim J, Im K, Oh S, Kim M, Lee J . Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses. Mov Disord. 2008; 24(2):237-45. DOI: 10.1002/mds.22347. View

Jin S, Oh M, Oh S, Oh J, Lee S, Chung S . Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism. Clin Nucl Med. 2016; 42(2):e80-e87. DOI: 10.1097/RLU.0000000000001474. View

Booij J, Kemp P . Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2007; 35(2):424-38. DOI: 10.1007/s00259-007-0621-0. View

Alberts I, Sachpekidis C, Prenosil G, Viscione M, Bohn K, Mingels C . Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [F]-FDG PET/CT. Ann Nucl Med. 2021; 35(4):485-492. PMC: 7981298. DOI: 10.1007/s12149-021-01588-6. View

Stiasny-Kolster K, Doerr Y, Moller J, Hoffken H, Behr T, Oertel W . Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2004; 128(Pt 1):126-37. DOI: 10.1093/brain/awh322. View

Szobot C, Shih M, Schaefer T, Junior N, Hoexter M, Fu Y . Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study. Neuroimage. 2008; 40(3):1195-201. DOI: 10.1016/j.neuroimage.2007.12.050. View

Lee Y, Oh J, Chung S, Chung S, Kim S, Nam C . Does smoking impact dopamine neuronal loss in de novo Parkinson disease?. Ann Neurol. 2017; 82(5):850-854. DOI: 10.1002/ana.25082. View

Lee S, Kim M, Lee J, Kim J, Kim M, Jo S . Clinical factors and dopamine transporter availability for the prediction of outcomes after globus pallidus deep brain stimulation in Parkinson's disease. Sci Rep. 2022; 12(1):16870. PMC: 9547008. DOI: 10.1038/s41598-022-19150-3. View

10.

Zhu Y, Tang X, Cheng Z, Dong Q, Ruan G . The Anti-Inflammatory Effect of Preventive Intervention with Ketogenic Diet Mediated by the Histone Acetylation of Promotor Region in Rat Parkinson's Disease Model: A Dual-Tracer PET Study. Parkinsons Dis. 2022; 2022:3506213. PMC: 9467749. DOI: 10.1155/2022/3506213. View

11.

Lundkvist C, Halldin C, Ginovart N, Swahn C, Farde L . [18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol. 1997; 24(7):621-7. DOI: 10.1016/s0969-8051(97)00077-2. View

12.

Mateos J, Lomena F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J . Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl). 2006; 191(3):805-11. DOI: 10.1007/s00213-006-0570-5. View

13.

Powell A, Ireland C, Lewis S . Visual Hallucinations and the Role of Medications in Parkinson's Disease: Triggers, Pathophysiology, and Management. J Neuropsychiatry Clin Neurosci. 2020; 32(4):334-343. DOI: 10.1176/appi.neuropsych.19110316. View

14.

Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi M . Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage. 2004; 21(4):1497-507. DOI: 10.1016/j.neuroimage.2003.12.014. View

15.

Kim C, Kim D, Hong I . Vascular Parkinsonism by Infarctions at Different Locations on 18F-FP-CIT PET/CT. Clin Nucl Med. 2019; 44(11):e627-e628. DOI: 10.1097/RLU.0000000000002721. View

16.

Coenen H, Dutschka K, Muller S, Geworski L, Farahati J, Reiners C . N.c.a. radiosynthesis of [123,124I]beta-CIT, plasma analysis and pharmacokinetic studies with SPECT and PET. Nucl Med Biol. 1995; 22(8):977-84. DOI: 10.1016/0969-8051(95)02067-5. View

17.

Lee C, Kim S, Oh S, Kim H, Yun S, Doudet D . Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson's disease. Ann Nucl Med. 2014; 28(9):874-9. DOI: 10.1007/s12149-014-0882-1. View

18.

Shin H, Chung S . Drug-induced parkinsonism. J Clin Neurol. 2012; 8(1):15-21. PMC: 3325428. DOI: 10.3988/jcn.2012.8.1.15. View

19.

Ahlskog J, Uitti R, OConnor M, Maraganore D, Matsumoto J, Stark K . The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord. 1999; 14(6):940-6. DOI: 10.1002/1531-8257(199911)14:6<940::aid-mds1005>3.0.co;2-y. View

20.

Innis R, Marek K, Sheff K, Zoghbi S, Castronuovo J, Feigin A . Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord. 1999; 14(3):436-42. DOI: 10.1002/1531-8257(199905)14:3<436::aid-mds1008>3.0.co;2-j. View